Phosphatidylinositol Glycan Anchor Biosynthesis Class U Protein in Breast Cancer
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA).
- Кому может быть актуально
- Состояния в реестре: Breast Cancer. Базовые параметры: 18 лет — 80 лет · Женщины.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Список центров уточняется — проверьте первичный протокол.
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Detection of Phosphatidylinositol Glycan Anchor Biosynthesis Class U Protein as Serum Biomarker for Breast Cancer
Обзор
The present study aims to evaluate the serum level of PIGU protein in patients with breast cancer and its relation with clinical, laboratory and pathological data of the patients.
Подробное описание
Breast cancer (BC) is the most common cancer among females. It is known to be the second leading cause of cancer-related deaths among women worldwide . Although the incidence rates of breast cancer vary between developed and developing nations, it continues to be the most prevalent form of cancer among women in Egypt, with an estimated mortality rate of approximately 11% in 2020 . Breast cancer is a heterogeneous disease, so treatment and prognosis vary based on tumor pathological type, histological grade, lymph node involvement, hormone receptor status and disease stage
* however even patients with similar prognostic features can experience different clinical outcomes after treatment . Despite significant advancements in early screening and diagnostic techniques, the incidence of breast cancer continues to rise annually, accounting for approximately 11.7% of all newly diagnosed cancer cases. So detection of new prognostic indicators is critical for selecting the optimal treatment modalities, evaluating the response and creating a follow-up plan to improve clinical outcome . Phosphatidylinositol glycan anchor biosynthesis class U (PIGU), also known as cell division cycle 91-like 1 (CDC91L1), is an important subunit of glycosylphosphatidylinositol transaminase (GPI-T) complex. It has been reported that the over-activity of certain components of the GPI T complex contributes to the development of various cancers, such as
breast cancer, bladder cancer, lymphoma, and non-small cell lung cancer. Studies have shown that PIGU has the potential to be a prognostic biomarker and therapeutic target for liver cancer, ovarian cancer and colorectal cancer . Also, PIGU expression levels have been associated with radiotherapy for differentiated thyroid cancer and the risk of cutaneous melanoma. It has been demonstrated that PIGU promotes hepatocellular carcinoma (HCC) progression via increasing HCC cell viability, migration, invasion and inhibiting apoptosis by activating the transcription factor nuclear factor-kappa B (NF-κB) pathway . Recent researches verify that PIGU protein levels were significantly higher in breast cancer patients compared to normal people
. So it was speculated that PIGU is playing an important role in tumor development, progression and it can be considered as a marker for breast cancer screening and prognosis (12).
Вмешательства
- Диагностический тест Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
Первичные конечные точки
- Detection of the serum level of PIGU protein in patients with breast cancer [Срок оценки: baseline]
Критерии участия
Критерии включения
- The study will be carried on female patients who diagnosed as breast cancer based on pathological and radiological confirmation, recruited from Clinical Oncology Departments and outpatient clinics, SECI, Assiut University
Критерии исключения
- Patients diagnosed with other concomitant cancer.
- Patients who have already received chemotherapy or radiotherapy.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Дизайн исследования
- Модель наблюдения
- Случай-контроль
Центры проведения
Список центров уточняется — проверьте первичный протокол.
Публикации
- An S, Liu F, Shi Y. Identification of serum phosphatidylinositol glycan anchor biosynthesis class U protein as diagnostic biomarker for breast cancer. Clin Chim Acta. 2025 Mar 1;569:120183. doi: 10.1016/j.cca.2025.120183. Epub 2025 Feb 6. PMID 39922250
- Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A, Siegel RL. Breast cancer statistics 2024. CA Cancer J Clin. 2024 Nov-Dec;74(6):477-495. doi: 10.3322/caac.21863. Epub 2024 Oct 1. PMID 39352042
- Azim HA, Elghazawy H, Ghazy RM, Abdelaziz AH, Abdelsalam M, Elzorkany A, Kassem L. Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis. JCO Glob Oncol. 2023 Mar;9:e2200387. doi: 10.1200/GO.22.00387. PMID 36888929
- Thakur N, Singh R, Sunigdha, Devgan R, Sharma A. Clinicopathological prognostic factors for survival in patients with breast cancer: a retrospective study from a tertiary cancer centre from North-West India. Ecancermedicalscience. 2025 Mar 6;19:1865. doi: 10.3332/ecancer.2025.1865. eCollection 2025. PMID 40492224
- Wei X, Yang W, Zhang F, Cheng F, Rao J, Lu L. PIGU promotes hepatocellular carcinoma progression through activating NF-kappaB pathway and increasing immune escape. Life Sci. 2020 Nov 1;260:118476. doi: 10.1016/j.lfs.2020.118476. Epub 2020 Sep 21. PMID 32971102
Идентификаторы
NCT: NCT07130162 · PIGU in breast cancer